AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

AGM Information Sep 7, 2023

7612_dva_2023-09-07_1b4e2171-617f-4b35-8259-d067656e0eaf.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 7643L

Eco Animal Health Group PLC

07 September 2023

7 September 2023

ECO Animal Health Group plc ("the Company")

(AIM: EAH)

Result of Annual General Meeting

ECO Animal Health Group plc announces that at its Annual General Meeting held earlier today ("AGM") all resolutions proposed to the meeting were duly passed.

Proxy votes received in relation to each resolution were as follows:

Resolution For % Discretionary % Against % Withheld
01 40,393,039 99.996 Nil 0.000 1,594 0.004 Nil
02 37,377,701 92.531 3,384 0.008 3,013,548 7.460 Nil
03 40,386,195 99.979 Nil 0.000 8,187 0.020 251
04 40,393,039 99.996 Nil 0.000 1,594 0.004 Nil
05 40,392,788 99.995 Nil 0.000 1,594 0.004 251
06 40,383,756 99.973 Nil 0.000 5,877 0.014 5,000
07 40,383,756 99.973 Nil 0.000 5,877 0.014 5,000

Contacts:

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)
020 8447 8899
IFC Advisory

Graham Herring

Zach Cohen
020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

George Tzimas

Sam Butcher
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Carlo Spingardi

Lydia Zychowska
020 7597 5970
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSMFDWEDSEIU

Talk to a Data Expert

Have a question? We'll get back to you promptly.